Physician profile

Carmen E Guerra

Hospitalist · Philadelphia, PA

NPI 1356373781

$6,641.36

in general payments reported to CMS, 2019-2025

5 companies · $4,400 in 2025

The $4,400 reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$4,400.00
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$295.63
Food and Beverage$133.07
Travel and Lodging$127.85

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Roche Molecular Systems, INC. $4,440.18 2024-2025
Glaxosmithkline, LLC. $1,642.50 2022
Astrazeneca Pharmaceuticals Lp $444.96 2021-2024
Novartis Pharmaceuticals Corporation $92.89 2024
E.R. Squibb & Sons, L.L.C. $20.83 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Carmen E Guerra

$6,641.36

in general payments reported 2019-2025

Years
2021-2025
Top company
Roche Molecular Systems, INC.
Context
The $4,400 reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).

https://glasscript.com/doctor/515813/carmen-e-guerra

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.